May 10, 2022 01:50 PM EDT
Pharma

UCB de­tails pos­i­tive piv­otal da­ta for myas­the­nia gravis, days af­ter As­traZeneca scores OK for Soliris suc­ces­sor

Tyler Patchen

News Reporter

UCB is tee­ing up a slate of new reg­u­la­to­ry fil­ings af­ter spelling out Phase III suc­cess­es for a pair of ex­per­i­men­tal drugs be­ing test­ed for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Fed­er­al ap­peals court says Te­va must delist Or­ange Book in­haler patents

A service from the Financial Times